A phase 2 dose optimisation study of ASLAN003 for the treatment of Acute Myeloid Leukaemia (AML).
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs ASLAN 003 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2017 New trial record
- 13 Nov 2017 According to an ASLAN Pharmaceuticals media release, Investigational New Drug (IND) application has been approved by Singapores Health Sciences Authority to initiate this trial.